IRadimed Corporation (IRMD)
Automate Your Wheel Strategy on IRMD
With Tiblio's Option Bot, you can configure your own wheel strategy including IRMD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
3 Medical Instrument Stocks Tapping GenAI to Navigate Industry Woes
Published: March 23, 2026 by: Zacks Investment Research
Sentiment: Negative
GMED, TCMD and IRMD tap GenAI to boost diagnostics and workflows, but high costs, regulation gaps and macro pressures still weigh on MedTech growth.
Read More
IRADIMED CORPORATION (IRMD) Q4 2025 Earnings Call Transcript
Published: February 10, 2026 by: Seeking Alpha
Sentiment: Neutral
IRADIMED CORPORATION (IRMD) Q4 2025 Earnings Call Transcript
Read More
IRADIMED CORPORATION (IRMD) Q3 2025 Earnings Call Transcript
Published: November 03, 2025 by: Seeking Alpha
Sentiment: Neutral
IRADIMED CORPORATION ( IRMD ) Q3 2025 Earnings Call November 3, 2025 11:00 AM EST Company Participants Roger Susi - Founder, Chairman, CEO & President John Glenn - CFO & Corporate Secretary Conference Call Participants Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Kyle Bauser - ROTH Capital Partners, LLC, Research Division Presentation Operator Welcome to the IRADIMED CORPORATION Third Quarter 2025 Financial Results Conference Call. [Operator Instructions] This call is being recorded today, November 3, 2025, and contains time-sensitive accurate information that is valid only for today.
Read More
What Makes iRadimed (IRMD) a New Buy Stock
Published: September 18, 2025 by: Zacks Investment Research
Sentiment: Positive
iRadimed (IRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
IRadimed: Continued Value Unlock With Extensive Reinvestment Runway
Published: August 21, 2025 by: Seeking Alpha
Sentiment: Positive
IRadimed Corporation demonstrates exceptional economic characteristics, with high NOPAT margins, robust free cash flow, and consistent value creation for shareholders. Management has effectively reinvested capital, generating over $18 in market value for every $1 invested since FY'22, and consistently exceeding a 12% ROIC hurdle rate. Despite modest sales growth, IRMD's profitability and cash conversion remain strong, with a persistent ability to redeploy earnings at attractive returns.
Read More
Recent Price Trend in iRadimed (IRMD) is Your Friend, Here's Why
Published: August 07, 2025 by: Zacks Investment Research
Sentiment: Positive
iRadimed (IRMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Read More
IRADIMED CORPORATION (IRMD) Q2 2025 Earnings Call Transcript
Published: August 01, 2025 by: Seeking Alpha
Sentiment: Neutral
IRADIMED CORPORATION (NASDAQ:IRMD ) Q2 2025 Earnings Conference Call August 1, 2025 11:00 AM ET Company Participants John F. Glenn - CFO & Corporate Secretary Roger E.
Read More
iRadimed (IRMD) Q2 Earnings and Revenues Surpass Estimates
Published: August 01, 2025 by: Zacks Investment Research
Sentiment: Positive
iRadimed (IRMD) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.42 per share a year ago.
Read More
IRADIMED CORPORATION (IRMD) Q1 2025 Earnings Call Transcript
Published: May 05, 2025 by: Seeking Alpha
Sentiment: Neutral
IRADIMED CORPORATION (NASDAQ:IRMD ) Q1 2025 Earnings Conference Call May 5, 2025 9:00 AM ET Company Participants Roger Susi - Founder, President & CEO John Glenn - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Operator Welcome to the IRADIMED Corporation First Quarter of 2025 Financial Results Conference Call. Currently, all participants are in a listen-only mode.
Read More
IRadimed (IRMD) Lags Q1 Earnings Estimates
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Negative
IRadimed (IRMD) came out with quarterly earnings of $0.42 per share, missing the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.36 per share a year ago.
Read More
CORRECTION -- IRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by IRADIMED CORPORATION (NASDAQ: IRMD), please note that in the first paragraph the date of the earnings call should read "Monday, May 5, 2025" instead of "Friday, May 5, 2025". The corrected release follows:
Read More
IRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
WINTER SPRINGS, Fla., April 28, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 first quarter financial results before the market opens on Friday, May 5, 2025. Iradimed management will host a conference call the same day beginning at 9:00 a.m. Eastern Time to discuss those results and to answer questions.
Read More
IRadimed Corporation: Steady, Low-Risk Grower In The Devices Space
Published: April 08, 2025 by: Seeking Alpha
Sentiment: Positive
IRadimed Corporation offers steady revenue growth with 14 consecutive quarters of record revenue and a small dividend, despite recent stock price decline. IRMD's unique MRI-compatible IV infusion pump and patient monitoring system face limited competition, ensuring a strong market position. Financials show robust performance with a 21% increase in US sales, but international sales dipped possibly due to cheaper alternatives in Asian markets.
Read More
About IRadimed Corporation (IRMD)
- IPO Date 2014-07-16
- Website https://www.iradimed.com
- Industry Medical - Devices
- CEO Roger E. Susi
- Employees 160